EP3487482A4 - New cannabis tablet formulations and compositions and methods of making the same - Google Patents

New cannabis tablet formulations and compositions and methods of making the same Download PDF

Info

Publication number
EP3487482A4
EP3487482A4 EP17835148.2A EP17835148A EP3487482A4 EP 3487482 A4 EP3487482 A4 EP 3487482A4 EP 17835148 A EP17835148 A EP 17835148A EP 3487482 A4 EP3487482 A4 EP 3487482A4
Authority
EP
European Patent Office
Prior art keywords
compositions
making
methods
same
tablet formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17835148.2A
Other languages
German (de)
French (fr)
Other versions
EP3487482A1 (en
Inventor
Kurt LEVY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Canopy Growth Corp
Original Assignee
Canopy Growth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61017335&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP3487482(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Canopy Growth Corp filed Critical Canopy Growth Corp
Publication of EP3487482A1 publication Critical patent/EP3487482A1/en
Publication of EP3487482A4 publication Critical patent/EP3487482A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP17835148.2A 2016-07-25 2017-07-25 New cannabis tablet formulations and compositions and methods of making the same Pending EP3487482A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662366517P 2016-07-25 2016-07-25
PCT/US2017/043808 WO2018022669A1 (en) 2016-07-25 2017-07-25 New cannabis tablet formulations and compositions and methods of making the same

Publications (2)

Publication Number Publication Date
EP3487482A1 EP3487482A1 (en) 2019-05-29
EP3487482A4 true EP3487482A4 (en) 2020-03-04

Family

ID=61017335

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17835148.2A Pending EP3487482A4 (en) 2016-07-25 2017-07-25 New cannabis tablet formulations and compositions and methods of making the same

Country Status (12)

Country Link
US (3) US20190183850A1 (en)
EP (1) EP3487482A4 (en)
CN (1) CN109789095A (en)
AU (1) AU2017302559A1 (en)
BR (1) BR112019001528A8 (en)
CA (1) CA3031533A1 (en)
CL (1) CL2019000198A1 (en)
CO (1) CO2019000787A2 (en)
IL (1) IL264386B2 (en)
MX (1) MX2019001121A (en)
PE (1) PE20200478A1 (en)
WO (1) WO2018022669A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019165117A1 (en) * 2018-02-23 2019-08-29 Columbia Care, Llc Hard-pressed scored splittable marijuana tablets
WO2019211772A1 (en) * 2018-05-03 2019-11-07 Radient Technologies Inc. Obtaining extracts in a solid form
WO2020092352A1 (en) * 2018-10-30 2020-05-07 Kelsie Biotech, Llc Tablets, formulations and methods for low melting point active ingredients
WO2020146753A1 (en) * 2019-01-10 2020-07-16 Columbia Care Llc Rapidly disintegrating oral tablet
US11633351B2 (en) 2019-12-13 2023-04-25 Nordiccan A/S Fast disintegrating cannabinoid tablets
US10925853B2 (en) 2019-04-17 2021-02-23 Nordiccan A/S Oral cannabinoid tablet
CA3040547C (en) 2019-04-17 2021-12-07 Medcan Pharma A/S Cannabinoid lozenge formulation
JP2023509675A (en) * 2020-01-08 2023-03-09 ソシエテ・デ・プロデュイ・ネスレ・エス・アー Oral solid cannabinoid oil composition for treating gastrointestinal disorders
CA3219553A1 (en) * 2021-05-21 2022-11-24 Rama JUDE Process for incorporating additives into aerosol-producing substrates and products made therefrom

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016084075A1 (en) * 2014-11-26 2016-06-02 One World Cannabis Ltd Synergistic use of cannabis for treating multiple myeloma
US20160166498A1 (en) * 2014-12-16 2016-06-16 Axim Biotechnologies, Inc. Oral care composition comprising cannabinoids

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2081474A1 (en) * 1990-05-08 1991-11-09 Manzer Durrani Direct spray-dried drug/lipid powder composition
AU6014098A (en) * 1996-12-31 1998-07-31 Inhale Therapeutic Systems Aerosolized hydrophobic drug
US6730330B2 (en) * 2001-02-14 2004-05-04 Gw Pharma Limited Pharmaceutical formulations
EP1361864B9 (en) * 2001-02-14 2014-07-09 GW Pharma Limited Liquid spray formulations for buccal delivery of cannabinoids
PA8576201A1 (en) * 2002-07-10 2004-05-26 Pfizer Prod Inc PHARMACEUTICAL COMPOSITION THAT HAS A DISTRIBUTION AND UNIFORM POWER OF FARMACO
ES2370062T3 (en) * 2006-09-15 2011-12-12 Echo Pharmaceuticals B.V. GRANULATE CONTAINING A PHARMACEUTICALLY ACTIVE SUBSTANCE AND AN EMULSIONANT AND METHOD FOR PRODUCTION.
CN101810593B (en) * 2010-05-10 2012-07-18 谢恬 Elemene sustained-release tablets
CA2992923C (en) * 2014-07-21 2021-06-29 Pharmaceutical Productions, Inc. Solid dosage form composition for buccal and sublingual administration of cannabinoids

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016084075A1 (en) * 2014-11-26 2016-06-02 One World Cannabis Ltd Synergistic use of cannabis for treating multiple myeloma
US20160166498A1 (en) * 2014-12-16 2016-06-16 Axim Biotechnologies, Inc. Oral care composition comprising cannabinoids

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2018022669A1 *

Also Published As

Publication number Publication date
CA3031533A1 (en) 2018-02-01
BR112019001528A8 (en) 2019-07-09
US20190183850A1 (en) 2019-06-20
CL2019000198A1 (en) 2019-05-31
US20220323403A1 (en) 2022-10-13
IL264386B2 (en) 2023-08-01
CN109789095A (en) 2019-05-21
US20210100771A1 (en) 2021-04-08
CO2019000787A2 (en) 2019-04-30
BR112019001528A2 (en) 2019-06-18
IL264386A (en) 2019-02-28
WO2018022669A1 (en) 2018-02-01
MX2019001121A (en) 2019-10-21
EP3487482A1 (en) 2019-05-29
PE20200478A1 (en) 2020-03-03
IL264386B1 (en) 2023-04-01
AU2017302559A1 (en) 2019-02-07

Similar Documents

Publication Publication Date Title
EP3704239A4 (en) Casz compositions and methods of use
EP3478308A4 (en) Cannabis compositions and methods
EP3337823A4 (en) Carrier-binding agent compositions and methods of making and using the same
EP3595653A4 (en) Compositions of plinabulin and use thereof
EP3704254A4 (en) Cas12c compositions and methods of use
EP3487482A4 (en) New cannabis tablet formulations and compositions and methods of making the same
EP3576782A4 (en) Construct-peptide compositions and methods of use thereof
EP3538122A4 (en) Cannabinoid formulations and method of making the same
EP3352577A4 (en) Cannabinoid compositions and methods of making
EP3129024A4 (en) Nicotine formulations and methods of making the same
EP3435956A4 (en) Photo-stabilized compositions and methods of use
EP3393655A4 (en) Fenfluramine compositions and methods of preparing the same
EP3532633A4 (en) Compositions and methods for the production of compounds
EP3436083A4 (en) Novel compositions and methods
EP3600372A4 (en) Synthekine compositions and methods of use
EP3310354A4 (en) Improved formulations of deferasirox and methods of making the same
EP3166892A4 (en) Scale-inhibition compositions and methods of making and using the same
EP3490569A4 (en) Topical compositions and methods of using thereof
EP3110891A4 (en) Low-voc compositions and methods of making and using the same
EP3436467A4 (en) Novel compositions and therapeutic methods
EP3478277A4 (en) Anti-acne compositions and methods of use
EP3528787A4 (en) Pharmaceutical formulations and methods of making the same
EP3349755A4 (en) Nicotine formulations and methods of making and using the same
EP3402443A4 (en) Devices and compositions and methods of use thereof
EP3551619A4 (en) Compositions comprising methylphenidate-prodrugs, processes of making and using the same

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190130

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CANOPY GROWTH CORPORATION

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20200205

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/02 20060101ALI20200130BHEP

Ipc: A61K 47/10 20170101ALI20200130BHEP

Ipc: A61K 9/16 20060101ALI20200130BHEP

Ipc: A61K 9/00 20060101ALI20200130BHEP

Ipc: A61K 9/14 20060101AFI20200130BHEP

Ipc: A61K 47/06 20060101ALI20200130BHEP

Ipc: A61K 9/20 20060101ALI20200130BHEP

Ipc: A61K 31/01 20060101ALI20200130BHEP

Ipc: A61K 47/38 20060101ALI20200130BHEP

Ipc: A61K 31/352 20060101ALI20200130BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20201117

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS